RxDoctor Payments Data

Momen Wahidi, MD

Pulmonary Disease · Chicago, ILNPI 1336223205

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (49.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Olympus Corporation Of The Americas at 55.6% of the total. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$779,332in general payments, 2019–2025

Across 1,145 payments — averaging $680.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$433K
  • Olympus America Inc.$63K
  • Cook Incorporated$47K
  • Spiration, Inc.$35K
  • Gyrus ACMI, Inc.$34K
  • Pulmonx Corporation$32K
  • plus $135K from 28 others
$360,573in research payments, 2019–2025

Across 67 payments — averaging $5381.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gyrus ACMI, Inc.$176K
  • Spiration, Inc.$61K
  • Veran Medical Technologies, Inc.$41K
  • Pulmonx Corporation$25K
  • Boston Scientific$22K
  • BD$18K
  • plus $17K from 2 others
$35,360in ownership & investment interests, 2019–2025

Across 1 payment — averaging $35,360 each. An ownership or investment interest held by the physician or an immediate family member.

  • Pleural Dynamics Inc.$35K

What the payments were for

  • Consulting fees$220,49328%
  • Speaking & faculty fees$95,12312%
  • Travel & lodging$59,4648%
  • Food & beverage$19,7613%
  • Education$384,49249%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$779,332 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$76,529
Medicare patients
187
Services billed
613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Albuterol Sulfate HfaAlbuterol Sulfate12$362

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →